Last reviewed · How we verify

NCT04423354

A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Ⅱ AEG

Status unknown NA Last updated 9 June 2020
What this trial tests

NA trial testing Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Type Ⅱ Adenocarcinoma of Esophagogastric Junction in Esophagogastric Junction Adenocarcinoma in 94 participants. Status unknown.

Timeline
25 March 2019
Primary endpoint
1 February 2024
31 March 2024

Quick facts

Lead sponsorGuangdong Provincial Hospital of Traditional Chinese Medicine
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment94
Start date25 March 2019
Primary completion1 February 2024
Estimated completion31 March 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Guangdong Provincial Hospital of Traditional Chinese Medicine

Who can join

Adults 18 to 78, any sex, with Esophagogastric Junction Adenocarcinoma or Siewert Type II Adenocarcinoma of Esophagogastric Junction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective: To evaluate the safety, feasibility and clinical efficacy of transthoracic single-hole assisted laparoscopic radical gastrectomy for Siewert Type Ⅱ adenocarcinoma of esophagogastric junction. Methods: A prospective, single-center, one-arm study will be performed. Patients who have been diagnosed with Siewert type Ⅱ esophagogastric junction adenocarcinoma and meet the eligibility criteria will be included in the study and undergo the transthoracic single-hole assisted laparoscopic radical gastrectomy. The data of preoperative, intraoperative, postoperative and follow-up will be recorded and analyzed. Primary study endpoints: The incidences of early postoperative complications and mortality. The secondary study endpoints:(1) Surgery and oncology indicators ;(2) Early postoperative recovery information ;(3) 3-year disease-free survival and overall survival rate;(4) 5-year disease-free survival and overall survival.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Feasibility and efficacy of transthoracic single-port assisted laparoscopic esophagogastrectomy for Siewert type II adenocarcinoma of the esophagogastric junction.
    Luo S, Xu J, Xiong W, Li J, et al · · 2021 · cited 3× · PMID 34790746 · DOI 10.21037/atm-21-4574

Verify or expand the search:

Other recruiting trials for Esophagogastric Junction Adenocarcinoma

Currently open trials in the same condition.

Other Guangdong Provincial Hospital of Traditional Chinese Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04423354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing